# BridgeBio Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bridgebio-pharma

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.bridgebio.com/
- Total disclosed funding: $434M
- Latest round: Series D (Jan 23, 2019)
- Investors on record: 9

## About

Based in California, US, and founded in 2014 by co-founders Neil Kumar Ph.D. (CEO), Seth Merrin, and Frank McCormick Ph.D., BridgeBio Pharma, Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing genetically targeted therapies for patients with genetic diseases related to cardiology, neurology, oncology, dermatology, and the endocrine system. In January 2024, BridgeBio Pharma, Inc. raised USD 450 million in venture debt funding from Blue Owl Capital.

The company provides a wide range of genetic disease therapies, such as NULIBRYTM (fosdenopterin), and focuses on advancing potential therapies for genetic conditions and cancers with genetic drivers. Additionally, the firm also provides patient advocacy and clinical trial development services.

## Funding rounds

- Series D, Jan 23, 2019, $299M — KKR, Hong Shan, Aisling Capital, Viking Global Investors, Hercules Capital, Corebridge Financial, Perceptive Advisors, Cormorant Capital
- Series C, Sep 13, 2017, $135M — KKR, Aisling Capital, Viking Global Investors, Janus Henderson Investors, Corebridge Financial, Perceptive Advisors, Cormorant Capital

## Investors

- KKR (https://capitalatlas.ai/funds/kkr) — Series C, Series D
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C, Series D
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C, Series D
- Janus Henderson Investors — Series C
- Corebridge Financial — Series C, Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C, Series D
- Cormorant Capital — Series C, Series D
- Hong Shan — Series D
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series D